- Home
- » Tags
- » Cantuzumab mertansine
Top View
- International Nonproprietary Names for Biological and Biotechnological Substances: a Review17
- The Power to Deliver Letter to Our Shareholders Immunogen, Inc
- Pharmaabkommen A1 E
- Prescrire's Contribution to the WHO Consultation on List 112 Of
- Customs Tariff - Schedule Xxi - 1
- Safety of Medicines
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
- Fate of Antibody-Drug Conjugates in Cancer Cells Cécile Chalouni1* and Sophia Doll2
- Immunogen, Inc. Announces Publication of Cantuzumab Mertansine Phase I Study in the Journal of Clinical Oncology
- Prescrire Contribution to Proposed INN List
- IMSN Open Letter on Antibody-Drug Conjugate 2151012
- (12) United States Patent (10) Patent No.: US 9,345,770 B2 Storkus Et Al
- Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma Ayad M
- Patient Selection Strategies to Maximize Therapeutic Index Of
- View the PDF Document
- Gm, Ke, Lr, Ls, Mw, Mz, Na, Rw, Sd, Sl, St, Sz, Tz, Ug, Zm, Zw
- Pharmacokinetics, Immunogenicity and Safety of Bivatuzumab
- "The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
- 1770.Full-Text.Pdf
- Immunogen, Inc. (Exact Name of Registrant As Specified in Its Charter)
- A Phase I Study of Cantuzumab Mertansine Administered As a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors
- (INN) for Biological and Biotechnological Substances
- Multiple Myeloma Cells +
- Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
- Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine
- Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri